Summit Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:SMMT

Comments

Summit Therapeutics Inc Earnings Estimates

SMMTNASDAQ

Trade with Public

$15.06

-0.32-2.08%

Last update: Mar 5, 9:30 AM

Overview NewsEarningsOptions Analyst Ratings Insider Trades Short Interest Stock Report

Summit Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:SMMT

Summit Therapeutics (SMMT) is scheduled to report Q1 earnings on April 30, 2026. Analysts estimate EPS of $-0.25 and quarterly revenue of $52.30K.

In the most recent quarter (Q4), Summit Therapeutics reported EPS of $-0.14, missing estimates of $-0.10 by 0.40%. Revenue came in at $0.00, missing the estimate of $56.78M by 1.00%.

Summit Therapeutics has missed EPS estimates in 3 consecutive quarters.

Over the last 4 quarters, Summit Therapeutics has averaged an EPS surprise of 0.44% and a revenue surprise of 1.00%.

Earnings Date

Apr 30

EPS Estimate

$-0.250

Quarterly Revenue Estimate

$52.30K

Annual Revenue
(as of Sep 30)

–

Summit Therapeutics Earnings History

Analyze the earnings history of Summit Therapeutics using advanced sorting and filters.

Summit Therapeutics (SMMT) Earnings Per Share

The chart below shows Summit Therapeutics's reported EPS compared to analyst estimates over recent quarters.

Summit Therapeutics (SMMT) Revenue

The chart below shows Summit Therapeutics's reported revenue compared to analyst estimates over recent quarters.

FAQ

When is Summit Therapeutics (NASDAQ:SMMT) reporting earnings?

Summit Therapeutics (SMMT) is scheduled to report earnings on April 30, 2026. The last reported earnings were for reported on February 23, 2026 for Q4.

What were the latest earnings per share (EPS) for Summit Therapeutics (NASDAQ:SMMT)?

The Actual EPS was $-0.14, which missed the estimate of $-0.10.

What were Summit Therapeutics’s (NASDAQ:SMMT) revenues?

The Actual Revenue was $0.00, which missed the estimate of $56.78M.

People Also Watch

Neurocrine Biosciences Inc

NASDAQ:NBIX

$130.40

-2.28%

Ionis Pharmaceuticals Inc

United Therapeutics Corp

Summit Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:SMMT

Summit Therapeutics (SMMT) is scheduled to report Q1 earnings on April 30, 2026. Analysts estimate EPS of $-0.25 and quarterly revenue of $52.30K.

In the most recent quarter (Q4), Summit Therapeutics reported EPS of $-0.14, missing estimates of $-0.10 by 0.40%. Revenue came in at $0.00, missing the estimate of $56.78M by 1.00%.

Summit Therapeutics has missed EPS estimates in 3 consecutive quarters.

Over the last 4 quarters, Summit Therapeutics has averaged an EPS surprise of 0.44% and a revenue surprise of 1.00%.

Earnings Date

Apr 30

EPS Estimate

$-0.250

Quarterly Revenue Estimate

$52.30K

Annual Revenue
(as of Sep 30)

–